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Abstract Aims/hypothesis. Linkage and association studies in Caucasian patients with Type II (non-insulin-dependent) diabetes mellitus suggest that one or more diabetes susceptibility gene(s) reside within human chromosome 20q12±13.1. This region of chromosome 20 contains the maturity-onset diabetes of the young type 1 gene, HNF4a. The purpose of this study was to assess the possible involvement of HNF4a in Type II diabetes. Methods. Mutation analysis was done on the 12 exons and promoter regions of the HNF4a gene in 182 Caucasian diabetic nephropathic patients and 100 Caucasian control subjects. The functional consequences of a novel promoter mutation were examined using a reporter system in the HepG2 liver cell line and electrophoretic mobility shift assays. Results. We identified two novel mutations in the HNF4a, an R323H missense mutation in exon 8, and a 7 bp deletion (D7) in the proximal promoter region resulting in deletion of a single putative Sp1 binding site. Using a reporter assay system, the D7 sequence was found to exhibit a 51.2 % (standard error ± 4.2 %) reduction in promoter activity relative to the normal sequence. In electrophoretic mobility shift assays using specific and non-specific competitors, the D7 sequence had a 45.5 % (range 40.4±46.6) reduction in binding compared with the normal sequence. The D7 allele occurs in a family with multiple cases of Type II diabetes in a pattern consistent with coinheritance of the D7 allele and diabetes. Conclusion/interpretation. Analysis of the HNF4a gene revealed two possible mutations in 182 diabetic patients which suggests that the HNF4a gene does not make a large contribution to diabetes susceptibility in the general population of Caucasian diabetic nephropathic patients. Functional analysis of the D7 promoter deletion suggests, however, that promoter mutations in otherwise normal genes could contribute to diabetes susceptibility. [Diabetologia (2000) 43: 364±372] cate studies have, however, confirmed evidence of linkage in other ethnic populations, so the extent to which these genetic loci contribute to Type II diabetes susceptibility in the general population is not clear.
Maturity-onset diabetes of the young (MODY) is a rare autosomal dominant form of Type II diabetes. It accounts for only 2±5 % of all cases of Type II diabetes and is characterised by an early age of onset ( < 25 years) and primary defects in insulin secretion [4, 5] . The recent cloning of five MODY genes have provided insight into factors regulating glucose homeostasis: hepatocyte nuclear factor 4 alpha (HNF4a) in MODY1 [6] , glucokinase in MODY2 [7] , hepatocyte nuclear factor 1 alpha (HNF4a) in MODY3 [8] , insulin promoter factor (IPF-1) in MODY4 [9] , hepatocyte nuclear factor 1 beta (HNF1b) in MODY5 [10] . Both HNF4a and 1a are transcription factors and are known to activate numerous genes involved in cholesterol, fatty acid, and glucose metabolism. They are expressed in a wide variety of tissue types including liver, kidney, small intestine, pancreas and muscle [11±12] . Although many different HNF1a mutations have been identified in MODY3 families [8, 13±19] , only eight potential mutations in HNF4a (Q268X, R154X, R127W, V393I, E276Q, F75fsdelT, G115S, I454V) have been identified in MODY1 families [6, 20±25] .
There have been four recent linkage studies evaluating American, French and Finnish Caucasian Type II diabetic families that have provided evidence of one, if not more than one, diabetes susceptibility locus on chromosome 20q12±13.1 (MODY1 region) [26±29] . In 1997, we reported evidence of linkage (p < 0.05) in Caucasian Type II diabetic sib-pairs to the polymorphic marker D20S197 [26] . A parallel study [27] reported evidence of linkage to three polymorphic markers in the MODY1 region (D20S119, D20S178, and D20S176) in Caucasian families with a preponderance of Type II affected members. Subsequently, evidence of linkage to polymorphic markers within, as well as, distal to the MODY1 region were reported in French Type II diabetic families [28] . In addition, the FUSION study (Finland-United States Investigation of NIDDM genetics), a large multicentre study consisting of 183 families with multiple Type II diabetic subjects, also observed linkage to chromosome 20 markers, namely D20S197 and a polymorphism near the adenosine deaminase gene (ADA) [29] . All four of these studies observed evidence of linkage to the MODY1 region (20q12±13.1), although the regions with the maximum linkage scores differed between the studies.
In an effort to more precisely map these suspected Type II diabetes loci, our laboratory did a case-control linkage disequilibrium analysis [30] . Multiple genetic markers in 20q12-q13.1 were genotyped in 182 unrelated Caucasian Type II diabetic nephropathic patients and allele frequencies were compared with a set of 100 DNA samples from age-matched, non-diabetic, normal Caucasian control subjects. Significant evidence of disequilibrium (p < 0.005) was observed at the ADA locus [30] . Because the MODY1 gene (HNF4a) resides in close proximity to the ADA locus [31±33], we examined the Type II diabetic nephropathic patients in our studies for HNF4a mutations to assess whether HNF4a mutations could contribute to diabetes in this cohort.
Subjects and methods
Subjects. The study cohort consisted of 182 incident Caucasian diabetic nephropathic patients collected as part of a clinical trial sponsored by Alteon, Inc. (Aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy). Patients enrolled in this study all had Type II diabetes mellitus with age of diagnosis after 35 years of age and overt proteinuria of more than 500 mg protein in a 24-h period. Diabetic nephropathy was assigned as a diagnosis in the presence of diabetic retinopathy through renal biopsy. In addition to renal evaluation, each patient was evaluated by an ophthalmologist by fundus photography or ophthalmoscopy or both or evaluation of patient records. Men had an average initial serum creatinine of 114 mmol/l or more and women had an initial serum creatinine of 96.8 mmol/l or more. These subjects had an average 16.1 7.7 years duration of diabetes (range 1±40 years), an average BMI of 33.0 6.2 (range 20.3±52.3), and had diabetic nephropathy at the time blood samples were collected. No family history data for diabetes or nephropathy was available for the study group. The control group consisted of 100 unrelated non-diabetic Caucasian subjects who were employees of North Carolina Baptist Hospital of Wake Forest University. After informed consent had been given a blood sample was taken for DNA isolation at the time of recruitment. Genomic DNA was isolated using the Puregene DNA isolation kit (Gentra, Minneapolis, Minn., USA).
After the D7 allele was identified in one patient with diabetic nephropathy, this patient was contacted and provided his family history. He was one of eight children born to two parents affected by Type II diabetes (his mother was unaware of her diabetes at first interview and his diabetic father was deceased). His mother and all siblings agreed to be screened for the presence of diabetes and nephropathy and to provide DNA for genetic analysis.
Analysis of HNF4a. The 12 exons, including splice junctions and 500 bp of the proximal promoter region of HNF4a were analysed by PCR followed by single strand conformational polymorphism (SSCP) analysis in the patient and control samples [6, 21] . We used 15 primer sets to amplify 200±400 bp products for the analysis. For each reaction, both primers were end-labelled with (g-32 P)ATP by T4 polynucleotide kinase (Stratagene, La Jolla, Calif., USA) according to the manufacturers' instructions. We did PCR on 25 ng of genomic DNA in a 15 ml volume containing 50 mmol/l KCl, 100 mmol/l TRIS-HCl pH 8.8, 1.5 mmol/l MgCl 2 , 0.2 mmol/l deoxyribonucleoside triphosphates (dNTPs), 0.1 pmol end-labelled primers, 6 pmol of each unlabelled primer and 1.0 U Taq polymerase. Samples were initially denatured for 5 min at 95°C and then cycled for 30 cycles of 40 s at 94°C, 40 s at annealing temperature (Tm ±3 to 5°C), 40 s at 72°C, followed by 5 min at 72°C as a final elongation. After PCR amplification, the products were diluted 1:10 in formamide loading dye (95 % formamide, 10 mmol/l NaOH, 0.25 % bromphenol blue, 0.25 % xylene cylanol), denatured for 2 min at 95°C and immediately placed on ice. The PCR products (1.7 ml) were separated by electrophoresis on 0.5X MDE acrylamide (FMC Bioproducts, Rockland, Md., USA), 0.6XTBE, ± 5 % glycerol non-denaturing polyacrylamide gels at 25°C at 15 W for 15 h. Gels were exposed to x-ray films overnight and checked for the presence of abnormal migration patterns. All products showing migration shifts and two products showing the predominant shift pattern were sequenced on both strands at the DNA Sequencing Core Laboratory of Wake Forest University School of Medicine using an ABI Prism 377 automated DNA sequencer (Applied Biosystems, Foster City, Calif., USA). Sequence similarity searching was carried out using the BLAST 2.0 analysis program ( [34] http://www.ncbi.nlm.nih.gov/BLAST/).
Reporter constructs and transient transfection assays. The normal and D7 deletion mutant promoter sequences were amplified by PCR using primers: Prom-F primer 5 ¢-CGGGGTACCCTCCCCGGCAGAGCCT-3 ¢ and Prom-R primer 5 ¢-CGGAATTCTTCTCCCTGCCTCCACGCC-3 ¢ (Fig. 1 ) and subsequently digested with KpnI and EcoRI before cloning into the pSEAP2-Enhancer vector (Clontech, Palo Alto, Calif., USA). We grew HepG2 cells in DMEM (GibcoBRL, Rockville, Md., USA) supplemented with 10 % fetal calf serum (FCS) in 5 % CO 2 . Cells were transfected in triplicate in three independent experiments using a modified calcium phosphate method [35] with 10 mg plasmid construct (pSEAP2-Enhancer ± HNF4a promoter sequences). Secreted alkaline phosphatase (SEAP) was measured using a chemiluminescence-luciferase assay (Clontech, Palo Alto, Calif., USA) according to manufacturers instructions 48 h after transfection. To normalise for transfection efficiency, 2 mg cytomegalovirus-driven b-galactosidase expression plasmid was transfected simultaneously and b-galactosidase activity was measured 48 h after transfection [36] .
Electrophoretic mobility shift assay (EMSA). Nuclear extracts were obtained from HepG2 cells. At 90 % confluency, HepG2 cells were washed twice in PBS. Adherent cells were resuspended in 40 mmol/l TRIS (pH 7.5), 1 mmol/l EDTA, 150 mmol/l NaCl by scraping. After a brief centrifugation, cells were washed twice in 10 mmol/l HEPES (pH 7.9), 1.5 mmol/l MgCl 2 , 10 mmol/l KCl, 1 mmol/l dithiothreitol, 1 mmol/l phenylmethylsulphonyl fluoride, 2 mg/ml leupeptin (all from Sigma, St. Louis, Mo., USA) and homogenised with a Type A/B Dounce homogenizer. Cells were collected by brief centrifugation, resuspended in 20 mmol/l HEPES (pH 7.9), 1.5 mmol/l MgCl 2 , 400 mmol/l NaCl, 10 % sucrose, 20 % glycerol, 0.2 mmol/l EDTA, 1 mmol/l phenylmethylsulfonyl fluoride (PMSF), 2 mg/ml leupeptin, and incubated on ice for 1 h. Nuclei were collected by centrifugation at 23 000´g for 60 min at 4°C. Nuclear proteins were recovered by overnight dialysis against 20 mmol/l HEPES, 1.5 mmol/l MgCl 2 20 % glycerol, 0.2 mmol/l EDTA, 1 mmol/l dithiothreitol, 1 mmol/l PMSF and 2 mg/ml leupeptin (Buffer C). The nuclear proteins were collected and the protein concentrations were determined by the Bradford assay (Bio-Rad laboratory, Hercules, Calif., USA). Complimentary oligonucleotides representing consensus Sp1 5 ¢-ATTCGATCGGGGCGGGGCGAGC-3 ¢ [37], TFIID 5 ¢-GCAGAGCATATAAGGTGAGGTAGGA-3 ¢ [37], normal promoter 5 ¢-GAGGCAGTGGGAGGGCG-GAGGGCGGGGGCCTT-3 ¢ and mutant promoter 5 ¢-GAG-GCAGTGGGAGGGCGGGGGCCTT-3 ¢ were annealed and 4 pmols were 5 ¢end-labelled with (g-32 P)ATP using T4 polynucleotide kinase (Stratagene, La Jolla, Calif., USA) according to the manufacturer's protocol. Binding reactions were done by pre-incubating 5 mg of nuclear extract proteins with or without unlabelled competitor DNA (at 10´, 25´, or 50´excess) in Buffer C plus 1 mg poly dI/dC for 10 min on ice in a 30 ml volume. Double stranded end-labelled oligonucleotide (40 fmol) was then added and incubated for 30 min on ice. Loading dye was added and 7 ml of the samples were loaded onto a 5 % polyacrylamide gel (29:1 acrylamide:bisacrylamide) + 1.25 % glycerol prepared in 0.5XTBE. Electrophoresis was done at 4°C and 250 V for 2 h. Gels were fixed in 10 % acetic acid/10 % isopropanol, dried and analysed using a Phosphor Imager 445 SI (Molecular Dynamics, Sunnyville, Calif., USA). Bound complexes were quantified from six independent experiments.
Genotyping and clinical evaluation of the WFUBMC 2137 (D7) family. All first-degree adult relatives of the D7 proband were evaluated for the presence of the D7 mutation and for clinical measures of Type II diabetes and nephropathy. Family members participated in the study after informed consent was obtained. Genotype analysis was carried out by PCR amplification of the proximal promoter region for each individual DNA sample, followed by SSCP analysis. The normal and D7 deletion mutant promoter sequences were amplified from each of them by PCR using the following [g-32 P]dATP (ICN The PCR products were denatured and analysed by electrophoresis on denaturing 8 % polyacrylamide gels at 60 W for 3 h. Gels were exposed overnight to x-ray film (Fuji, Stamford, Conn., USA) between intensifying screens. Clinical analysis consisted of measurement of glycated haemoglobin concentration, urine protein:creatinine ratio, serum creatinine and blood urea nitrogen concentrations. Data on age, height, weight and age of diagnosis of diabetes were collected along with the patients initial and current diabetic therapy (diet, insulin, oral agents) and anti-hypertensive (angiotensin converting enzyme inhibitor) therapy.
Results
Previous linkage and linkage disequilibrium studies from this and other laboratories have suggested the presence of at least one, possibly two, Type II diabetes susceptibility loci on chromosome 20q12±13.1 [26±29]. Due to the previous identification of the HNF4a as a diabetogenic gene, we did mutation analysis of the HNF4a gene in 182 unrelated Type II diabetic nephropathic patients which in an earlier study [30] exhibited significant evidence of linkage disequilibrium to an allele of a polymorphic marker (ADA) residing in close proximity to the HNF4a gene. The results of these analyses are shown in Table 1 . Within introns 1A and 1B three previously reported polymorphisms were identified in both patient and control samples and two reported coding changes in exons 1C and 4 were also identified [38, 39] . No differences in the frequencies of the polymorphisms or mutations or both were observed between the Type II diabetic patients and control groups, corroborating results from other studies [21, 22, 38] . We identified two novel alleles in the Type II diabetic patient group, a 7 bp deletion (denoted D7) in the promoter region and an Arg®His mutation (R323H) in exon 8. These two mutations were not present in the 100 control samples. One patient carried a 7 bp deletion (D7) in the promoter region of HNF4a. This patient had a BMI of 44.2 and age of onset of 35 years. The D7 mutation occurred 102 bp upstream from the initiation codon. The deleted 7 base pairs (5 ¢-GGAGGGC-3 ¢) are half of a direct repeat from the normal promoter sequence which contains two copies of the motif in a head to tail orientation (Fig. 1) . The 14 base pairs of the normal HNF4a promoter (5 ¢-GGAGGGC-3 ¢´2) corresponds to two putative consensus binding sites for the Sp1 transcription factor (5 ¢-N(G/ A)GGCGN(G/A)N-3 ¢) (Fig. 1) . The D7 promoter contains only one consensus Sp1 binding site. Sp1 is a ubiquitously expressed transcription factor known to activate the transcription of numerous genes [40] . Deletion of clustered or isolated Sp1 sites from the promoter regions of genes can affect the transcriptional activation [41±44]. Consequently, observation of the D7 mutation in a diabetic subject suggested that altered expression of a normal HNF4a gene could be involved in diabetes susceptibility in this subject.
The effect of the D7 mutation on promoter activation was analysed using a reporter gene assay. A 187-base pair fragment of the normal HNF4a and a 180-base pair fragment the D7 promoter region were amplified by PCR (Prom-F to Prom-R in Fig. 1 ) and cloned into the pSEAP2-Enhancer vector (Clontech, Palo Alto, Calif., USA). This minimal promoter region contained the putative Sp1 binding site(s) and the NF1 transcription factor binding site [17] . Normal, D7, and control reporter constructs were transfected into HepG2 liver cells and secreted alkaline phosphatase representing promoter activity was measured. The construct containing the D7 allele resulted in a 51.2 % (standard error ± 4.1 %) reduction in promoter activity relative to the intact sequence containing two Sp1 sites (Fig. 2) .
Electrophoretic mobility shift assays (EMSA)/gel retardation assays, using specific and non-specific oligonucleotide competitors, were done to evaluate the effect of the D7 allele on transcription factor binding to recognition sequences (Fig. 3) . Three retarded complexes, (Fig. 3A) were observed when radiola- belled normal sequence ( Fig. 1) was incubated in the presence of HepG2 nuclear extracts. All three bands were specifically competed away using the unlabelled normal sequence. By comparison, competition of the radiolabelled normal sequence with unlabelled D7 sequence resulted in an average 45.5 % (range 40.4 % to 46.5 %) less efficient competition in concentrations from 2 to 50-fold excess of labelled normal sequence (Fig. 3B) . Similar migrating protein-DNA complexes were observed when a radiolabelled consensus Sp1 sequence was used as a probe in the gel retardation assays (arrows in Fig. 3C ). When unlabelled normal and D7 sequences were used as competitors in the binding assays with labelled Sp1, all bands were specifically competed with the D7 sequence showing an average 47.3 % (range 35.8 % to 51.4 %) less efficient competition at competitor concentrations from 5 to 75-fold (Fig. 3D) . When recombinant human Sp1 protein (Promega, Madison, Wis., USA) was used in place of the nuclear extract, similar protein-DNA complexes, three shifted bands, were observed (data not shown). These results indicate that proteins bind the normal sequence more efficiently than the deleted sequence. In addition to the molecular evaluation of the D7, we have evaluated the effect of this putative mutation by genotyping additional family members. The family has been designated WFUBMC 3137. Segregation of the D7 mutation is broadly consistent with the presence of diabetes in the family (Fig. 4) . The proband has seven siblings and a mother who is still living. Of the family members six carry the D7 mutation: the mother, the proband, two sisters and two brothers. Of these D7 positive family members all have diabetes except for one sister. This sister (age 45, BMI 44.6) has a high normal Hb1 Ac and could progress to frank diabetes in the future. There were three siblings who did not inherit the D7 mutation and one of these has Type II diabetes. Age of diagnosis for affected family members ranges from 39±67 years which is more consistent with Type II diabetes than with MODY. The proband and his four diabetic siblings are currently treated with oral hypoglycaemic agents or dietary control. There was one, the mother, who was unaware of her diabetes and was not receiving any treatment. No member of the family has received insulin therapy. In addition to the segregation of the D7 mutation in the family, the major clinical observation was the considerable obesity in the family with six siblings and the mother having BMIs greater than 40. Of the siblings four with the D7 mutation had either microalbuminuria or overt nephropathy or endstage renal disease or both suggesting the possibility that D7 can confer a particularly severe form of Type II diabetes causing renal target organ damage.
Discussion
We have screened the HNF4a gene, including both coding and promoter regions, for mutations in a group of 182 Caucasian diabetic nephropathic patients who had a genetic association with the closely linked ADA locus in an earlier study [30] . This study identified five previously reported polymorphsims or mutations, or both which are not considered to affect HNF4a function [6, 20, 21, 38, 39] . We observed no statistically significant differences in the frequencies of these sequence variants between the Type II diabetic patients and control subjects. These data further support the hypothesis that these reported polymorphisms do not contribute to Type II diabetes susceptibility in this group. We identified two novel HNF4a mutations in the Type II diabetic group, one in the extreme carboxy terminal region of exon 8 (R323H) which awaits functional characterisation. This mutation was observed in one allele of one patient (age of onset 46 years, BMI 35.54) and not found in any of the 100 healthy control subjects. This mutation results in a semiconservative substitution in the carboxy terminal end of the HNF4a protein. This amino acid is conserved in HNF4 isoforms from other species including Drosophila, Aedes aegypti, Bombyx mori, Xenopus, rat and mouse. All known isoforms of HNF4a contain exon 8 but deletion studies have suggested that the extreme carboxy terminal domain of HNF4a is not required for promoter binding or activation [45] . This does, however, not exclude a possible alteration of HNF4a activity by the R323H mutation.
The proximal promoter region of HNF4a contains binding sites for numerous transcription factors including AP1 (activator protein 1), HNF-3, HNF1a Fig. 2 . Reduction of promoter activity in D7 promoter. pSEAP2 Enhancer + normal (N), + D7, and alone (control) were transfected into HepG2 cells along with pCMV b-Gal. Secreted alkaline phosphatase, representing promoter activity, was measured at 48 h and normalised to b-gal activity. All three independent transfections were done in triplicate with the normal construct representing 100 % activity (means ± SEM, n = 3) and NF-1 (nuclear factor 1) [17] that are conserved in mice and humans. In the Caucasian Type II diabetic subjects (n = 182) and control subjects (n = 100) in the current study, no mutations were identified in any of these sites. This is consistent with other studies of the promoter region of the HNF4a gene which have also failed to identify mutations in these conserved transcription factor binding sites [20, 38] .
We did however identify a 7 bp deletion (D7) in the proximal promoter region resulting in deletion of a single putative Sp1 binding site. This second novel mutation (D7 promoter mutation) was characterised using both reporter assays and gel retardation assays which showed an average 50 % reduction in activation and binding of the D7 mutation compared with the normal promoter sequence suggesting the mutation could have a pronounced effect on HNF4a gene expression. The D7 promoter mutation deletes one of two putative Sp1 transcription factor binding sites. Generally Sp1 is considered a ubiquitously expressed transcription fac- normal promoter sequence, D7 promoter sequence. C Competition of consensus Sp1 binding site with normal promoter, D7 promoter and Sp1 sequences. D Quantitative analysis of competition of consensus Sp1 DNA-protein complexes with increasing normal and D7 promoter competitor concentrations.
normal promoter sequence, D7 promoter sequence tor involved in the regulation of numerous eukaryotic and viral genes particularly those with TATA-less promoters [44] . Sequence similarity searching of the 14 bp normal promoter sequence showed 100 % identity to many gene promoter regions including: rat plateletderived growth factor A gene (PDGF-A), human calcium activated neutral protease large subunit (mu-CANP), human multiple exostosis 2 gene (EXT2), endomembrane proton pump subunit, mouse t complex testis specific protein (Tctex2) and dog CD34. The low probability (p < 0.05) of detecting this 14-base pair sequence in this context suggests that it is of some functional relevance.
Clustered or multiple Sp1 binding sites have been found in the promoter regions of many genes. The functional properties of repeated Sp1 binding sites has been evaluated in numerous studies. Deletion of four clustered Sp1 sites in the promoter region of the insulin receptor gene resulted in inefficient expression of the gene [42] . Binding of Sp1 to the three repeated Sp1 binding sites of the PDGF-A chain promoter resulted in synergistic activation and suggested that cooperativity between bound Sp1 proteins is important in gene activation. Deletion of at least one of the three Sp1 binding sites resulted in a 70 % reduction of promoter activity [41] . Additional support for the importance of repeated Sp1 binding sites is found in the a2-integrin gene promoter, which contains two repeated Sp1 sites. Deletion of one Sp1 binding site resulted in 80±90 % reduction in promoter activity, whereas the deletion of both Sp1 binding sites abolished promoter activity [43] . Our evaluation of the D7 promoter mutation, which deletes one of two Sp1 binding sites and results in a 50 % reduction of promoter activity, is consistent with these studies.
The decrease in transcriptional activation of the D7 mutation is consistent with this mutation being associated with diabetes. Functional characterisation of the two previously identified premature termination mutations (Q268X, R154X) in MODY1 families, indicate that the diabetic phenotype is due to the loss of functional HNF4a protein, as opposed to a gain of function from the mutant protein [6, 46] . The loss of functional HNF4a protein in the termination mutations is thought to be exacerbated in tissues where there is low HNF4a expression (e. g. pancreas). Recent characterisation of the E276Q mutation suggests that haploinsufficiency as well as a weak dominant negative effect contribute to the Type II diabetic phenotype [46] . Our finding of a 50 % reduction in activation and binding in the D7 promoter mutation is consistent with this hypothesis. It is not clear whether the patient with the D7 promoter mutation has MODY or conventional Type II diabetes. The patient's age of diagnosis is early (35 years) and the pa- and DMDx: age at Type II diabetes diagnosis tient has extreme obesity (BMI 44.2). We hypothesise that the D7-associated reduction in HNF4a expression combined with obesity contributes to diabetes in this patient.
This hypothesis is largely supported by an evaluation of the family (WFUBMC 2137) of the proband. Of six family members with the D7 mutation five have diabetes and two of three family members without the D7 mutation do not have diabetes. The absence of complete correlation of the D7 mutation with diabetes is not surprising for a common, late-onset disease and consistent with the presentation of other families harbouring HNF4a mutations [21, 22] . The one D7 positive sibling without clinical diabetes has a high normal Hb1 Ac and could yet progress to overt diabetes. In addition, the one diabetic sibling who is D7 negative could easily have diabetes from another aetiology. The expression and EMSA studies suggest that the D7 mutation probably leads to a 50 % reduction in expression of HNF4a from the mutated chromosome, leading to a 25 % reduction in the potential expression of HNF4a in a cell. Because a 50 % reduction in HNF4a expression in people with protein truncation mutations leads to early-onset diabetes, it is not surprising that a 25 % reduction in HNF4a expression, associated with substantial obesity, in the WFUBMC 2137 family could lead to later-onset diabetes. This analysis of the D7 promoter suggests promoter mutations that alter the expression of diabetogenic genes, such as HNF4a have the ability to confer a disease phenotype in people carrying such alleles even though the coding sequence of the gene is normal.
The two new mutations described in this report (the R323H in exon 8 and the D7 promoter mutation) are not sufficient to explain the evidence of linkage disequilibrium observed in our Type II diabetic nephropathic patient group. It should be noted that SSCP could have a detection rate of 80±90 % [48] and thus, we might not have detected all DNA-sequence differences. It is, however, unlikely that such sequence differences would identify a substantial number of new mutations in the cohort we screened. The low number of mutations in the coding and proximal promoter region of HNF4a in the patient group which shows association with chromosome 20 is consistent with other studies [6, 20, 21, 38, 39] . Therefore, the question still remains, which gene or genes on chromosome 20 are contributing to Type II diabetes susceptibility? A possibility is that other Type II diabetic susceptibility gene(s), residing near HNF4a, are responsible for the evidence of linkage and linkage disequilibrium of Type II diabetes to chromosome 20.
